Pawlukianiec Cezary, Gryciuk Małgorzata Ewa, Mil Kacper Maksymilian, Żendzian-Piotrowska Małgorzata, Zalewska Anna, Maciejczyk Mateusz
Students Scientific Club "Biochemistry of Civilization Diseases" at the Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 2c Mickiewicza Street, 15-233 Bialystok, Poland.
Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 2c Mickiewicza Street, 15-233 Bialystok, Poland.
Pharmaceuticals (Basel). 2020 Sep 10;13(9):240. doi: 10.3390/ph13090240.
Meloxicam is a non-steroidal anti-inflammatory drug, which has a preferential inhibitory effect to cyclooxyganase-2 (COX-2). Although the drug inhibits prostaglandin synthesis, the exact mechanism of meloxicam is still unknown. This is the first study to assess the effect of meloxicam on protein glyco-oxidation as well as antioxidant activity. For this purpose, we used an in vitro model of oxidized bovine serum albumin (BSA). Glucose, fructose, ribose, glyoxal and methylglyoxal were used as glycating agents, while chloramine T was used as an oxidant. We evaluated the antioxidant properties of albumin (2,2-di-phenyl-1-picrylhydrazyl radical scavenging capacity, total antioxidant capacity and ferric reducing antioxidant power), the intensity of protein glycation (Amadori products, advanced glycation end products) and glyco-oxidation (dityrosine, kynurenine, N-formylkynurenine, tryptophan and amyloid-β) as well as the content of protein oxidation products (advanced oxidation protein products, carbonyl groups and thiol groups). We have demonstrated that meloxicam enhances the antioxidant properties of albumin and prevents the protein oxidation and glycation under the influence of various factors such as sugars, aldehydes and oxidants. Importantly, the antioxidant and anti-glycating activity is similar to that of routinely used antioxidants such as captopril, Trolox, reduced glutathione and lipoic acid as well as protein glycation inhibitors (aminoguanidine). Pleiotropic action of meloxicam may increase the effectiveness of anti-inflammatory treatment in diseases with oxidative stress etiology.
美洛昔康是一种非甾体抗炎药，对环氧化酶-2（COX-2）具有优先抑制作用。尽管该药物抑制前列腺素合成，但其确切机制仍不清楚。这是第一项评估美洛昔康对蛋白质糖基氧化以及抗氧化活性影响的研究。为此，我们使用了氧化牛血清白蛋白（BSA）的体外模型。葡萄糖、果糖、核糖、乙二醛和甲基乙二醛用作糖基化剂，而氯胺T用作氧化剂。我们评估了白蛋白的抗氧化特性（2,2-二苯基-1-苦基肼自由基清除能力、总抗氧化能力和铁还原抗氧化能力）、蛋白质糖基化强度（阿马多里产物、晚期糖基化终产物）和糖基氧化（二酪氨酸、犬尿氨酸、N-甲酰犬尿氨酸、色氨酸和淀粉样β蛋白）以及蛋白质氧化产物的含量（晚期氧化蛋白产物、羰基和巯基）。我们已经证明，美洛昔康增强了白蛋白的抗氧化特性，并在糖、醛和氧化剂等各种因素的影响下防止蛋白质氧化和糖基化。重要的是，其抗氧化和抗糖基化活性与常用抗氧化剂如卡托普利、曲洛克斯、还原型谷胱甘肽和硫辛酸以及蛋白质糖基化抑制剂（氨基胍）相似。美洛昔康的多效作用可能会提高对具有氧化应激病因疾病的抗炎治疗效果。
